SAGE: Sage Therapeutics, Inc Company Profile & Statistics

About

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.

Info & Links

CEO

Barry E. Greene

Headquarters

55 CAMBRIDGE PARKWAY
CAMBRIDGE, MA 02142, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

353

Sage Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization²

459.57M

Enterprise Value

414.35M

Enterprise Value/EBITDA(ttm)

-1.07

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

10.66

Price to Book(mrq)

0.94

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

80.75%

Operating Margin(ttm)

-971.50%

Profit Margin(ttm)

-791.58%

Return on Equity(ttm)

-68.18%

Return on Invested Capital(ttm)

-69.10%

Return on Assets(ttm)

-60.84%

Income Statement

Revenue(ttm)

47.40M

Revenue Per Share(ttm)

0.76

Gross Profit(ttm)

38.57M

EBITDA(ttm)³

-387.25M

Net Income Available to Common(ttm)

-354.40M

Diluted EPS(ttm)

-6.59

Share Statistics

Beta (5Y Monthly)

0.94

52-Week Change

-46.38%

S&P 500 52-Week Change

12.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

62.62M

Dividend Yield

0.00%

Float⁴

58.10M

% Held by Insiders

5.50%

% Held by Institutions

99.22%

Balance Sheet

Total Cash(mrq)

423.85M

Total Cash Per Share(mrq)

6.77

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

9.13%

Quick Ratio(mrq)

7.42%

Book Value Per Share(mrq)

6.55

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.32

Free Cash Flow(ytd)

-81.73M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SAGE

Sage Therapeutics, Inc

Sage Therapeutics, Inc Profile